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Abstract: Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates down-
stream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell pro-
liferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is 
a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In 
recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR 
drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of 
cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and 
its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are an-
ticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new 
class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new 
head and neck cancer therapies. 
Keywords: Anti-EGFR patents, EGFR, EGFR overexpression, head and neck squamous cell carcinoma, tyrosine kinase in-
hibtors, targeted therapies. 
1. INTRODUCTION  
 Head and neck cancer is the sixth most common cancer 
worldwide with a global incidence between 400,000 and 
600,000 new cases per year and a mortality rate of 300,000 
deaths annually [1-3]. It comprises a spectrum of malignan-
cies that, develop primarily within the oral cavity, pharynx, 
and larynx. Squamous cell carcinoma is the principal his-
tologic subtype of this disease, accounting for more than 
90% of all cases [4, 5]. The high incidence and mortality rate 
make these cancers a significant public health problem [6]. 
Head and neck squamous cell carcinoma (HNSCC) patients 
have a 50% five year survival rate, which is highly depend-
ent on the stage at diagnosis [7]. Accurate assessment of 
clinical symptoms, physical examination and laboratory re-
sults are of paramount importance to guide diagnostic ap-
proaches, staging and choice of therapy [8]. 
 The treatment plan depends upon patient and disease-
related factors, such as the site of the primary tumor, the 
stage of the disease (early-stage vs. advanced-stage), feasibil-
ity of organ preservation, the ECOG performance status 
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(Eastern Cooperative Oncology Group), significant comor-
bidities and the goal of therapy [8]. Patients harboring early 
stage disease (stage I and II) are potentially curable with 
single modality treatments (either surgery or radiation). Ad-
vanced disease patients (stage III and IV) require a multidis-
ciplinary and multimodality approach with a combination of 
surgery, radio- and chemotherapy [8]. Despite recent ad-
vances in radio- and chemotherapy, survival rates of HNSCC 
patients remain poor. Local recurrences are frequent and 20-
30% of cases will develop metastatic disease [9]. 
 Extensive surgeries involving the resection of the pri-
mary tumor and cervical lymph nodes usually cause func-
tional and aesthetic consequences, having a great impact on a 
patient’s quality of life [8]. The standard treatment for most 
patients is currently multimodal, and includes combined 
chemotherapy and radiotherapy. Moreover, the addition of 
induction chemotherapy (IC) remains an appropriate ap-
proach for advanced disease with a high risk of local or dis-
tant failure [8]. Platinum and taxane combinations are the 
backbone of several IC regimens for locally advanced head 
and neck cancers (LAHNSCC) and the TPF (docetaxel, cis-
platin and fluorouracil) regimen is the most accepted induc-
tion regimen for LAHNSCC [10].  
 Tobacco and alcohol use are the most common risk fac-
tors for HNSCC and the human papillomavirus (HPV) has 
been recently established as a cause of oropharyngeal cancer 
[11, 12]. Tobacco use is the main risk factor for HNSCC 
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carcinogenesis, with smokers having a 5 to 25 fold risk com-
pared to non-smokers [13], due to the genotoxic effects of 
carcinogenic substances in tobacco [14]. Alcohol consump-
tion is relevant for HNSCC development for its capacity to 
synergistically enhance the carcinogenic effects of tobacco 
[15]. Moreover, the acetaldehyde metabolite forms DNA 
adducts that interfere with synthesis and repair [16].  
 HPV is found in 23-35% of all HNSCC biopsies [17] and 
in 45-90% of oropharyngeal cancers [17-20]. HPV-16 is the 
most prevalent subtype, occurring in 87-90% of HPV-
positive oropharyngeal cancers [21-23]. A recent compre-
hensive integrative genomic analysis of HNSCC and HPV 
status was performed by mapping RNA-Seq reads of 279 
patients and it was observed that 12% (36/279) were 
HPV(+). Of 33 oropharyngeal tumours, 64% (21/33) were 
positive for HPV. The HPV(+) subset of oropharyngeal 
HNSCCs, exhibited a loss of TRAF3 (TNF Receptor-
Associated Factor 3), activating mutation of PIK3CA, and 
amplification of E2F1 (E2F Transcription Factor 1) involv-
ing NF-kB, activation. In HPV(+) HNSCCs, the most 
prominent findings were subsets containing amplicons on 
11q with CCND1, FADD, BIRC2 and YAP1 and mutually 
exclusive CASP8 and HRAS mutations. Importantly, these 
findings in HPV-associated cases may have the potential to 
be used as tools for treatment decisions [24].  
 Recently, molecular alterations underlying HNSCC tu-
morigenesis have been explored [24-29]. One of the pivotal 
molecules is the EGFR, which is overexpressed in more than 
90% of HNSCCs [30, 31]. EGFR is upregulated not only in 
HNSCC but also in the vast majority of solid tumors, becom-
ing, therefore, a major target for molecular therapies [32, 33].  
 Based on EGFR expression in HNSCC, cetuximab, a 
chimeric monoclonal antibody that binds with high affinity 
to the EGFR, has been used in the United States since 2006 
as first-line treatment in combination with radiation therapy 
for LAHNSCC [34] or as a single agent for patients with 
metastatic disease and poor responses to platinum-based 
regimens [35]. In 2011, combinations of cetuximab with 
other agents were approved by the U.S. Food and Drug Ad-
ministration for the first line of treatment of HNSCC. 
Cetuximab combination therapy with cisplatin or carboplatin 
and 5-fluorouracil was based on a multi-center clinical study 
involving 442 participants that, demonstrated an improve-
ment in survival [36].  
 In the present review, we will perform an updated as-
sessment of EGFR biology in HNSCC and its clinical im-
pact, with a special emphasis on novel, multi-target EGFR-
inhibitors, which may transform HNSCC therapy. 
2. EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) 
 The EGFR was discovered in the 1970s. Cohen and col-
leagues isolated a protein that caused precocious tooth erup-
tion in neonatal mice, now known as EGF (epidermal growth 
factor) [37]. A few years later, the same research group iden-
tified a high level of radio-labeled EGF bound to the cyto-
plasmic membrane of A431 squamous carcinoma cell lines. 
This was the first evidence of a membrane receptor with af-
finity to EGF, the EGFR [38]. 
 EGFR belongs to the ErbB receptor family (EGFR, 
ErbB2/Neu/Her2, ErbB3/Her3 and ErbB4/Her4), and the pro-
tein is composed of 1210 amino acids with four extracellular 
domains (ED), a transmembrane domain (TD) and an intracel-
lular tyrosine kinase domain (TKD) (Fig. 1). Its carboxyl-
terminal tail contains several phosphorylation sites: one serine 
residue (Ser-1142), one threonine residue (Thr-654) and seven 
tyrosine residues (Try-845, 992, 1045, 1068, 1086, 1148, 
1173) [39, 40]. EGFR can be activated by several specific 
ligands: (1) Amphiregulin, (2) Betacellulin, (3) Epiregulin, (4) 
Neuregulin, (5) Heparin-binding EGF, (6) Transforming 
growth factor alpha (TGF-) and (7) EGF (Fig. 1). Under 
normal physiological conditions, all four ErbB receptors can 
form 10 possible dimer combinations including 4 homodimers 
and 6 heterodimers. Each combination has specific affinity for 
signaling in effective intracellular pathways [40, 41] (Fig. 1).  
 EGFR ligands cause a conformational change, resulting 
in domain II interaction and receptor dimerization (Fig. 1) 
[39]. In addition, EGFR phosphorylation sites can activate 
downstream protein kinases such as the Src kinase family, 
protein kinase C and protein kinase A. EGFR itself is also 
able to phosphorylate other protein residues and target 
downstream signaling such as the MAPK, STAT and 
PI3K/AKT pathways, which control cell survival, prolifera-
tion, migration, differentiation, and adhesion [42-45].  
2.1. EGFR Deregulation in Tumors 
 Due to its significance in the regulation of multiple cellu-
lar mechanisms, EGFR homeostasis is key to normal func-
tion. Inasmuch, EGFR activity and regulation is tightly con-
trolled by a plethora of mechanisms including copy number 
variation, single nucleotide polymorphism (SNP), alternative 
splicing, phosphorylation, ligand availability, dimerization 
partner availability, trafficking and degradation [46]. In the 
pathogenesis of cancer, EGF/EGFR is deregulated at several 
levels, namely: autocrine/paracrine factors; gene amplifica-
tion; gene mutations, and protein nuclear translocation. All 
of these alterations lead to overexpression or constitutive 
activation of related signaling pathways (Fig. 1). 
2.1.1. Autocrine/Paracrine Factors 
 EGFR-mediated neoplastic transformation may be ef-
fected by autocrine/paracrine mechanisms of overexpression 
of both EGFR and its ligands, providing multiple advantages 
to tumors through the promotion of cell proliferation, sur-
vival, angiogenesis, invasion and metastasis. Most studies 
that have analyzed EGFR protein in HNSCC patients, used 
immunohistochemistry (IHC) methodologies on paraffin-
embedded tumor samples, and described EGFR overexpres-
sion in 43 to 100% of cases (Table 1). These discrepancies 
between EGFR overexpression rates might be the result of 
the type of antibodies or fixative used, differences in IHC 
technique, and storage time of samples. Nevertheless, the 
biological role of EGFR overexpression in HNSCC is un-
questionably significant. Interestingly, a recent meta-analysis 
evaluated EGFR expression as a prognostic factor in 
HNSCC [47]. This meta-analysis included 37 studies and 
found that overall, EGFR overexpression was associated 
with reduced overall survival (OS) hazard ratio (HR) of 
1.694, 95 % confidence interval (CI): 1.432–2.004) [47]. 
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 A majority of carcinomas express EGF-like growth fac-
tors that, contribute to increased signaling mediated by 
EGFR activation [45, 48]. A decade ago, the co-expression 
of EGFR and its ligands in the tumor microenvironment was 
hypothesized to have an important role in carcinogenesis and 
progression in patients with HNSCC [49]. Recently, The 
Cancer Genome Atlas (TCGA) offered a comprehensive and 
extensive landscape of somatic genomic alterations in 
HNSCC patients, including mRNA expression levels of the 
ErbB family ligands (supplementary Table 1). In total, HRG, 
NRG4 and NGR1 mRNA levels, were upregulated in 15, 7 
and 6% of cases, respectively, while EGF, AREG and EREG 
mRNA levels were upregulated in 4% of cases [24].  
 The TNF gene family, although it typically has low 
mRNA expression levels (2%) [24], is implicated with 
autocrine neoplastic transformation and increased prolifera-
tion in HNSCC cell lines [50]. In the clinical setting, patients 
with upregulated TNF mRNA expression had an overall sur-
vival estimate of 12.98 months compared to patients with 
normal TNF expression (21.85 months) (supplementary Ta-
ble 1). Amphiregulin (AREG) overexpression is associated 
with an increased risk of developing breast cancer [51], lung, 
colorectal, ovary and prostate carcinomas [52]. AREG over-
expression was detected in 4% (12/279) of HNSCC patients 
and associated with a mean overall survival of 28.29 months 
compared to 21.75 months for patients with normal expres-
sion (supplementary Table 1). Heparin binding-EGF (HB-
EGF) is an EGF mainly produced by monocytes and macro-
phages. Some studies have associated HB-EGF expression 
with the development of malignant phenotypes including a 
metastatic mechanism that displays aggressive tumor behav-
ior [53, 54]. HB-EGFR is upregulated in human breast carci-
nomas, ovarian, gastric, melanoma and glioblastoma tumor 
cell lines [55-57]. In HNSCC, HB-EGF expression is altered 
in 4% (11/279) of cases (supplementary Table 1). Heregulin 
(HRG) is the most expressed ligand in HNSCC patients and 
present in 15% (46/279) of cases (supplementary Table 1). 
Interestingly, patients with HRG mRNA upregulation have a 
higher mean overall survival (42.32 months) compared to 
patients with normal expression levels (21.85 months) (sup-
plementary Table 1). 
2.1.2. EGFR Amplification 
 Gene amplification of the EGFR has been observed in 
distinct tumors, including gliomas, colorectal, esophageal, 
breast and pancreatic cancers [58-64]. Several studies have 
detected increased EGFR copy number in HNSCC patients 
ranging from 7.8 to 58% (Table 1). The most comprehensive 
study was performed by the TCGA and reported a frequency 
of 11% of EGFR gene amplification, which induced EGFR 
overexpression, therefore demonstrating its pathogenic effect 
[24]. In addition, the authors showed EGFR gene amplifica-
tion was associated with worse patient outcomes, with over-
all survival of 17.15 months in EGFR amplified cases versus 
26.41 months in patients without gene amplification [24].  
2.1.3. EGFR Mutation 
 The majority of the EGFR somatic mutations identified 
in tumors are concentrated in the extracellular and intracellu-
lar tyrosine kinase domains, clustered in specific areas, 
which assumes the role of mutational hot spots. Initial stud-
ies in lung cancer showed the importance of mutations in-
volving exons 18, 19, 20 and 21, which encode a portion of 
 
Fig. (1). A- ErbB family receptor: EGFR/HER1, ErbB2/Neu/Her2, ErbB3/Her3 and ErbB4/Her4. All ErbB family receptors, except ErbB2 
bind to specific ligands allowingthe improvement of receptor dimerization. B- Multiple combinations of homodimers receptor (4) and het-
erodimers receptor (6). Receptor phosphorylation promotes the activation of intracellular pathways that control proliferation, angiogenesis 
and metastasis. C- Cetuximab action, the only chemotherapeutic agent against EGFR, approved for use in HNSCC patients. The monoclonal 
antibody competes with the ligand and blocks dimerization and phosphorylation receptor. 
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the EGFR tyrosine kinases domains [65]. These mutations 
predict patient responses to anti-EGFR drugs, such as er-
lotinib and gefitinib, and are assessed on a routine basis 
[65].  
 In HNSCC, the data available is more limited. Despite a 
disparity of published research, a low frequency of EGFR 
somatic mutations has also been reported in these tumors 
(Table 1). Nagalakshmi et al, using SSCP followed by se-
quencing, observed a mutation frequency of 81.4% in cases. 
In contrast, other studies and more recently, the TCGA con-
sortium, showed that EGFR mutations are rare events, pre-
sent in less than 10% of cases (Table 1, Supplementary Table 
2) [24, 66, 67]. The lack of EGFR somatic mutations in 
available HNSCC cell lines reinforce the absence of this 
event in HNSCC tumorigenic process [68].  
 One mutation in HNSCC that has gained particular atten-
tion is the EGFRvIII, which is located in the extracellular 
domain [69]. The EGFRvIII is described by an in-frame de-
letion of 267 amino acids in the extracellular domain, result-
ing in the loss of exons 2 to 7. The instability in the extracel-
lular domain of EGFRvIII results in significant functional 
changes in the EGFR and acquires constitutive tyrosine 
kinase activity [70]. This mutation was first detected in 
glioblastomas, and later studies reported its presence and 
importance in HNSCC (Table 1). The first studies used im-
munohistochemistry and reverse transcription-PCR, and 
Table 1. Review of EGFR Molecular Alterations in HNSCC. 
Expression  Amplification  TK Domain Mutations Other Mutations (EGFRvIII) 
Author  Date 
% (N) Methods  % (N) Methods % (N) Methods % (N) Methods 
Chung et al. 2006 - - 58% (49/86) FISH - -   
Sok. J.C. et al. 2006 - - - - - - 
42% (14/33)/ 
21% (7/33) 
IHC/RT-
PCR 
Payne, C. et al. 2006 2006 - - - - 8% (2/24) HRMAA - - 
Sheikh Ali. et al. 2008 32% (21/65) IHC - - 0% (0/91) Sanger - - 
Al-Swiahb et al. 2010 
83.63% 
(195/220) 
IHC - - - - - - 
Hong A. et al. 2010 87%(216/249) IHC - - - - - - 
Numico G. et al. 2010 35% (43/122) IHC - - - - - - 
Young R.J. et al. 2011 87% (81/93) IHC 20% (41/204) FISH - - - - 
Nakata Y. et al. 2011 82% (73/89) IHC 36% (32/89) FISH - - - - 
Pectasides E. et al. 2011 50% (32/64) IHC 17% (11/64) FISH - - - - 
Chau. N.G. et al 2011       42% (22/53) RT-PCR 
Huang S.F. et al. 2012 46.88% (75/160) IHC - - - - - - 
Sweeny. L. et al. 2012 56% (28/50) IHC - - - - - - 
Smilek. P. et al. 2012       20.7% (6/29) RT-PCR 
Maiti G. P. et al. 2013 84% (37/44) IHC 26.4% (47/178) DPCR - - - - 
Rossle M. et al. 2013 100% (119) IHC 7.8% (9/115) FISH - - - - 
Chang J. Y. et al. 2013 63.9% (69/108) IHC   - - - - 
Gröbe A. et al. 2014 95% (196/206) IHC - - - - - - 
Nagalakshmi K. et al. 2014 
- - - - 
81.39% 
(104/129) 
SSCP/ 
Sanger  
-  
Melchers. L.J. et al. 2014 - - - - - - 
8% (42/531)/ 
0% (0/97) 
IHC/RT-
PCR 
TCGA 2015 
47% (17/279) 
RNA 
Seq. 
11% (31/279) 
DNA 
Seq. 
4.65% (13/279) DNA seq. 0.35% (1/279)  
Khattri. A. et al. 2015 - - - - - - 0.38% (2/540) RT-PCR 
IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization; DPCR: differential polymerase chain reaction; RT-PCR: Reverse transcription polymerase chain reaction; 
HRMAA: High-resolution melting amplicon analysis; SSCP: single-strand chain polymorphis; RNA Seq: RNA Sequencing.  
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Table 2. Anti-EGFR Agents and Multi-Target Action. Recent Clinical Trials for HNSCC 
Anti-EGFR Agent Manufacturer Target Patent Number Phase Clinical Trial Number 
Monoclonal Antibodies 
Cetuximab Bristol-Myers Squibb EGFR US20040170632 A1 Approval n.a 
Panitumumab Amgen Oncology EGFR WO2013181572 A2 Approval n.a 
Nimotuzumab CIMYM Bioscience EGFR 
-- 
 II and III 
NCT01425736, 
NCT00910117, 
NCT00702481 
Zalutumumab Genmab EGFR -- III NCT00496652 
MEHD7945A Roche EGFR, HER3 US20130259867 A1 I and II  NCT01577173 
RO5083945 Roche EGFR -- I NCT01046266 
Sym004 Merck KGaA EGFR US7887805 B2 II NCT01417936 
Reversible Tyrosine Kinase Inhibitors 
Erlotinib  Osi Pharms Inc. EGFR RE41065 III NCT00442455 
Lapatinib GlaxoSmithKline Inc. EGFR, HER2 and HER4 US8513262 B2 II, II,II 
NCI200901492, 
NCT01711658, 
NCT00424255 
Irreversible Tyrosine Kinase Inhibitors 
Afatinib  
Boehringer Ingelheim, 
Inc. 
EGFR, EGFR  L858R, E746_A750, L858R/T790M 
and HER2 
WO2013052157A1 II, II, III 
NCT01538381, 
NCT01721525, 
NCT01345682 
AST-1306 
Allist Pharmaceuticals 
Inc. 
EFGR, EFGRT790M/L858R  HER2 and 
HER4 
US 20080300248 
A1 
II ChiCTR-ONC-10000893 
AZD9291 AstraZeneca. Inc. EGFR WT,  L858R/T790M WO 2013014448 n.a n.a 
CNX-2006 Clovis Oncology, Inc. EGFR L858R, L858R/T790M WO2013014448 n.a n.a 
CO-1686 Clovis Oncology, Inc. EGFR WT,  L858R/T790M -   n.a 
CUDC-101 Curis, Inc. EGFR, HER 2 and HDAC US7547781 B2 I NCT01384799 
Dacomitinib Pfizer Inc. EGFR, HER2 and HER4 CN 103288758 A II NCT01737008  
Icotinib 
Zhejiang Beta Pharma 
Inc. 
EGFR, EGFR L858R, L861Q , T790M US20110182882 A1 II NCT02328261 
Pelitinib Wyeth Inc. 
EGFR, HER2, Src, MEK/ERK, Raf, c-
Met, CDK4 
CN 103275002 A I NCT00098501 
Other Inhibition Approaches 
EGFR Antisense    EGFR -   - 
n.a: not available. 
 
detected EGFRvIII in approximately 40% of cases. In vitro 
studies were also performed, suggesting a biological role in 
HNSCC tumorigenesis and (cetuximab) therapy response 
[71]. The presence of EGFRvIII in HNSCC was also re-
ported by other authors in frequencies varying from 8-42% 
(Table 1). However, more recent studies (including the 
TCGA consortium) performed using more accurate method-
ologies do not confirm these findings and report an absence 
or very low frequency of EGFRvIII in HNSCC (Table 1) 
[72-74].  
2.1.4. Protein Nuclear Translocation 
 The first discovery of nuclear translocation was observed 
in hepatocyte regeneration studies in the last decade [75]. 
Additionally, EGFR internalization and nuclear translocation 
has been demonstrated in different healthy tissue types such 
as the uterus of pregnant mice and mouse embryos [76]. The 
classic EGFR translocation mechanism occurs in proteins 
containing nuclear localization sequences (NLS) that interact 
with importin / protein, which mediates interactions with 
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the nuclear pore complex (NPC) [77]. Subsequently, EGFR 
nuclear localization is correlated with increased cellular pro-
liferation, supporting the role of EGFR as a transcription 
factor of cyclin D1 genes [78] that mediate synthesis of pro-
liferating cell nuclear antigen (PCNA), which is a DNA po-
lymerase delta cofactor [79]. Over the last decade, several 
studies have suggested that, nuclear expression of EGFR 
may be an important molecular determinant of resistance to 
cetuximab therapy [80]. Specifically, EGFR nuclear translo-
cation was evaluated in a cetuximab-resistant cell line that 
demonstrated increased nuclear localization of EGFR, medi-
ated by the Yes and Lyn proteins which belong to Src family 
kinase family [81]. Furthermore, a non-invasive methodol-
ogy to monitor the response to EGFR-inhibitor treatment has 
been tested in mice with HNSCC xenografts using [64] Cu-
cetuximab-F(ab')2, an EGFR-directed PET tracer [82] or 
(111) In-cetuximab-F(ab')(2) [83]. An experimental ap-
proach observed that EGFR nuclear translocation is associ-
ated with DNA-PKcs in DNA repair after exposure to cis-
platin or ionizing radiation (IR), and is required for the repair 
of DNA damage [84]. The role of EGFR traffic has been 
associated with HNSCC resistance to multimodal therapy. 
The use of radiolabeled EGFR-inhibitors may be an efficient 
tool to monitor clinical response [85].  
3. EGFR INHIBITORS 
 Due to the central role of EGFR in several tumors, the 
scientific community and pharmaceutical companies de-
signed agents that could specifically inhibit EGFR. Two ma-
jor strategies were developed: monoclonal antibodies 
(mAbs) and small molecule tyrosine kinase inhibitors 
(TKIs).  
3.1. Monoclonal Antibodies 
 Cetuximab (Erbitux
®
, Bristol-Myers Squibb; New York, 
NY.) is a chimeric human-murine monoclonal antibody that 
binds competitively to EGFR. Cetuximab is 152 kDa, made 
up of four polypeptide chains: two heavy (lambda) chains 
(449 amino acids) and two light (kappa) chains (214 amino 
acids). Both chains contain one and two consensus sequences 
for N-linked glycosylation [86]. Cetuximab prevents stimula-
tion by EGF and TNF- endogenous ligands, disrupting in-
tracellular signaling [87]. Blocking this receptor reduces 
proliferation, metastasis, angiogenesis and increases apopto-
sis levels [88]. In February 12, 2004, the Food and Drug 
Administration (FDA) approved cetuximab in combination 
with irinotecan, for the treatment of metastatic colorectal 
carcinoma in patients refractory to irinotecan-based chemo-
therapy [89]. In 2006, cetuximab was approved by the FDA 
[90] for the treatment of LAHNSCC and is so far the only 
anti-EGFR agent for its treatment in combination with radia-
tion and chemotherapy, or as a monotherapy for recurrent, 
metastatic HNSCC that is unresponsive to platinum-based 
chemotherapy [36]. 
 In the Phase III EXTREME trial, patients with recurrent 
or metastatic HNSCC were treated with a chemo/cetuximab 
combination had prolonged overall survival rates compared 
with patients treated with chemotherapy alone (median 10.1 
versus 7.4 months, HR for death 0.80, 95% CI 0.64 to 0.99) 
[91]. However, in Eastern Cooperative Oncology Group 
Study phase III, patients with metastatic or recurrent HNSCC 
were randomized to cisplatin plus placebo or cisplatin plus 
cetuximab. Progression-free survival (PFS) and overall sur-
vival (OS) were not significantly improved [92].  
 Panitumimab (Vectibix®, Amgen, Thousand Oaks, CA, 
USA) is anti-EGFR monoclonal antibody that has been 
evaluated as an adjuctive therapy to traditional chemotherapy 
(cisplatin and 5-fluorouracil) in HNSCC patients. However, 
a Phase III study (SPECTRUM trial) did not show and im-
provement in OS in patients with recurrent or metastatic 
HNSCC, but did show an improvement in PFS and had an 
acceptable toxicity profile [93]. Another study demonstrated 
that among patients with a positive HPV status, as assessed 
by p16 immunohisstochemistry, showed increased PFS after 
treatment with cisplatin and fluorouracil plus panitumumab. 
Therefore, the authors suggested that p16 status might be 
important considerations in future trials with HNSCC pa-
tients [93].  
 Currently, clinical trials are using the combination of 
panitumumab in combination with other chemotherapeutic 
agents. At present, the benefit of combined panitumumab 
and paclitaxel therapy as a first-line treatment is being con-
ducted in HNSCC patients (NCT01264328). 
 Nimotuzumab (TheraCIM, CIMYM Bioscience, Ontario, 
Canada) is another type of humanized chimeric monoclonal 
antibody. It binds to different epitopes in domain III of the 
extracellular region of EGFR. Several Phase I, II and III tri-
als have been conducted in patients with HNSCC 
(NCT01425736, NCT00910117 and NCT00702481). A re-
cent phase II pharmacodynamic trial of nimotuzumab was 
conducted in 10 unresectable HNSCC patients and demon-
strated positive results, and also there was no evidence of 
skin rashes during 8 weeks of treatment [94]. An advanced 
approach is being carried to evaluate the association of nimo-
tuzumab in combination with DCF (docetaxel, cisplatin and 
5-fluorouracil) in recurrent or metastatic HNSCC 
(NCT01425736) [95]. An ongoing Phase II trial 
(NCT00702481) intends to define the response and toxicities 
associated with the addition of nimotuzumab to chemoradia-
tion based on cisplatin for LAHNSCC. Additionally, Nizo-
tumubab plus radiotherapy combination therapy was con-
ducted in 106 advanced HNSCC patients, and showed a sig-
nificant survival improvement for nimotuzumab treated pa-
tients [96]. 
 Zalutumumab (Genmab; Copenhagen, Denmark) is a 
anti-EGFR mAb entirely humanized with high-affinity to 
EGFR. Twenty eight patients with metastatic/recurrent 
HNSCC were treated with zalutumumab and showed a re-
sponse rate of only 7.1% and the most frequently adverse 
effects (AEs) reported in Phase I/II studies were infusion-
related reactions, rash/acne, and dyspnea [97]. Furthermore, 
286 HNSCC patients resistant to platinum-based chemother-
apy showed a significant improvement in PFS (p = 0.0012) 
when treated with zalutumumab, and a trend in improved OS 
(6.7 months vs. 5.2 months in zalutumab vs. control groups, 
respectively; HR, 0.77; 95% CI, 0.57-1.05; P = 0.0648) [98]. 
Zalutumumab has also failed to show increased loco-regional 
control and 3-year disease specific or overall survival in an-
other randomized phase III study (NCT00496652). This 
study was conducted by the Danish Head and Neck Cancer 
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Consortium (DAHANCA) and aimed to evaluate if concur-
rent treatment with zalutumumab during RT improved out-
comes in patients with HNSCC.  
 MEHD7945A (Roche, Genentech, South San Francisco, 
CA), is a mAb against EGFR and HER3 that inhibits the 
binding of specific ligands dependent on EGFR- and HER3- 
mediated downstream signaling [99]. This monoclonal anti-
body has modulated radiation responses in lung and head and 
HNSCC. Preclinical studies have demonstrated that 
MEHD7945A in combination with radiation is more cyto-
toxic in comparison to individual anti-EGFR or anti-HER3 
antibodies using xenograft models. The dual EGFR/HER3 
targeting action of MEHD7945A merits further investigation 
and clinical trial evaluation [100].  
 RO5083945 (Roche, Genentech, South San Francisco, 
CA) is a glyco-engineered anti-EGFR IgG1 mAb with a high 
affinity for all FcRIIIa variants. An antibody-dependent 
cellular cytotoxicity assay (ADCC) showed increased activ-
ity of RO5083945 compared to cetuximab and panitumu-
mab. Preclinical approaches provided steps for the clinical 
trial recruitment. The pharmacodynamics investigation has 
been conducted in patients with KRAS mutated tumors in an 
open label multicenter in patients with operable HNSCC 
(Data not published; NCT01046266). 
 Sym004 (MerckKGaA) is a novel combination between 
992 and 1024 antibodies, directed against different non-
overlapping epitopes in the extracellular domain of EGFR, 
with a superior anticancer efficacy compared with existing 
mAbs. Additionally, the antibody mixture showed a potent 
inhibition of cell growth, efficient inhibition of ligand bind-
ing and also the internalization and degradation of EGFR 
[101]. More recently, the efficacy and tolerability of 
Sym004, was investigated in recurrent and/or metastatic 
HNSCC patients (NCT01417936). The results showed mod-
erate anti-tumor activity of Sym004 in patients (reduced dis-
ease progression at 6 months in 12% of patients). In addition, 
the safety profile of the Sym004 was comparable to other 
anti-EGFR mAbs [102]. For this reason, Sym004 represents 
a promise in treatment of HNSCC patients, mainly those that 
are cetuximab-refractory.  
3.2. Tyrosine Kinase Inhibitors -TKIs 
 TKIs are small molecules that can bind directly into the 
adenosine triphosphate (ATP) of the tyrosine kinase domain 
(TKD), thus inhibiting the intracellular signaling pathways 
[103]. Currently, there are a variety of multi-targeted small 
molecule tyrosine kinase inhibitors under investigation in 
Phase II and III trials in different HNSCC therapeutic set-
tings with the potential to significantly modify the approach 
to anti-EGFR therapy for HNSCC.  
 The first TKI approved by the FDA was gefitinib (Ir-
essa®, AstraZeneca, Inc.) for use in non-small-cell lung can-
cer (NSCLC) [104]. A Phase II study showed a tolerable 
cytotoxic action rate and a response to neoadjuvant treatment 
in 18% of 22 HNSCC patients [105]. Furthermore, the re-
sponse rate (RR) was 10.6%, median OS was 8.1 months, 
and 1-year OS rate was 29.2% in HNSCC patients (n = 52) 
with metastatic or recurrent disease and tolerable levels of 
AEs were reported [106].  
 Erlotinib (Genentech; South San Francisco, CA.), also 
known as Tarceva,® is a TKI FDA-approved as a first-line 
treatment for NSCLC for patients with exon 19 deletions or 
exon 21 (L858R) EGFR mutations [107]. A Phase II study 
conducted recently with 21 HNSCC patients, showed an 
increase of 63% in overall survival and few adverse events, 
after treatment with erlotinib, cisplatin and radiotherapy 
[108]. In recent years, these clinical studies have supported 
use of erlotinib with other chemotherapeutic agents by dis-
playing an improvement in overall survival and acceptable 
levels of toxicity [109-111]. The effect of erlotinib mono-
therapy in combination with radiotherapy has been proposed 
as a Phase I/II trial (NCT00442455). So far, there is no pub-
lished data on cytotoxicity and clinical effects of this combi-
nation. Everolimus, an inhibitor of mammalian target of ra-
pamycin (mTOR), was combined with erlotinib in a clinical 
trial of patients with metastatic platinum-resistant HNSCC. 
This approach was based on the frequent activation of the 
mTOR pathway in HNSCC. Unfortunately, the trial showed 
little benefit, with a modest influence on immunosuppression 
and tumor growth [112]. Currently, a Phase II clinical trial is 
being conducted to evaluate the effect of docetaxel and cis-
platin combination with or without erlotinib, and is currently 
recruiting participants (NCT01064479).  
 Lapatinib (GlaxoSmithKline Inc.) also known as Tykerb® 
is a reversible TKI with high affinity for the EGFR and HER2 
receptor. Recently, this chemotherapy received FDA approval 
in combination with letrozole for patients with estrogen recep-
tor and HER2, and in combination with capecitabine 
(Xeloda®) for patients with advanced breast cancer [113], 
Few studies have evaluated lapatinib alone or in combination, 
which may be explained by the low rate of HER2 receptor 
expression in HNSCC tumors [114]. However, there is evi-
dence that the use of lapatinib prolongs tumor stabilization of 
salivary glands tumors at approximately 6 months (36% - 62 
patients) [115] and that combination with chemoradiotherapy 
increased the 6 month complete response rate post-
chemoradiotherapy [116]. Currently, there is one Phase II trial 
(NCI200901492) using the combination of lapatinib with 
capecitabine. Study objective include the evaluation of OS, 
PFS response rate, toxicity and quality of life. The THY-
HARD (NCT01711658) Phase II trial is recruiting HNSCC 
patients and evaluating the additive effects of radiotherapy 
plus cisplatin with or without lapatinib. Although lapatinib 
was initially considered a promising drug to treat HNSCC, a 
study testing adjuvant lapatinib in high-risk HNSCC after sur-
gery was terminated early by the sponsor when outcomes be-
tween the placebo and lapatinib arms were not observed to be 
different (data not published; NCT00424255). 
4. RECENT PATENTS (NEW GENERATION OF TKIs) 
 A variety of TKIs have been developed in recent years, 
and many of them tested in pre-clinical studies that show 
promising results against various tumor types. However, use 
is not approved for clinical use yet. Our review draws atten-
tion to promising chemotherapeutic agents in the treatment 
of HNSCC. 
 CUDC-101 (Curis, Inc.) 7-(4-(3-ethynylphenylamino)-7-
methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide is a 
recently discovered reversible TKI that has multiple molecu-
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lar targets (EGFR, HER2 and HDAC). A preclinical trial 
demonstrated increased anti-proliferative activity of CUDC-
101 in HNSCC cell lines, when compared to exposure with 
erlotinib, lapatinib or vorinostat combination [117]. Re-
cently, a Phase I trial, was conducted in twenty-five patients 
with advanced solid tumors who received incremental doses 
of CUDC-101. Preliminary evidence of antitumor activity 
was demonstrated with good tolerance levels [118]. Addi-
tionally, a Phase I trial was conducted in HNSCC to investi-
gate the safety and pharmacokinetics of CUDC-101 in com-
bination with cisplatin and radiation (data not published) 
(NCT01384799).  
 Icotinib (Zhejiang Beta Pharma Inc.)[1,4,7,10] tetraoxa-
cyclododecino[2,3-g]quinazolin-4-amine, N-(3-
ethynylphenyl)-7,8,10,11,13,14-hexahydro targets wild type 
and mutated EGFR variants (L858R, L861Q, T790M). The 
in vitro approach showed an increased anti-proliferative ef-
fect in A431 cell lines, while in in vivo studies, an antitumor 
effect was observed in nude mice of human tumor-derived 
xenografts [119]. Icotinib clinical trials, conducted in pa-
tients with advanced NSCLC, showed positive clinical anti-
tumor activities and acceptable toxicity in monotherapy or in 
combination [120, 121]. Although there are several clinical 
trials in other solid tumors such as NSCLC, esophageal and 
pancreatic cancers, there is only one Phase II clinical trial 
that is active but not recruiting patients with advanced naso-
pharyngeal carcinoma to evaluate the icotinib efficacy as a 
monotherapy (NCT02328261). 
 Irreversible TKIs covalently bind to a phosphorylation-
specific site in the intramembrane portion of their target, 
blocking the phosphorylation and subsequent activation of 
intracellular pathways. This class of molecules is known as 
the second-generation irreversible tyrosine kinase inhibitor 
and some irreversible TKIs are in advanced stages of clinical 
and preclinical testing approaches.  
 Afatinib (Gilotrif®, Boehringer Ingelheim, Inc.)((E)-N-
[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-
yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide 
[122] (Fig. 2A) is an irreversible HER family inhibitor that 
targets EGFR, HER-2, and HER-4. The FDA approved 
afatinib as a first-line treatment of NSCLC patients with 
exon 19 deletions or exon 21 (L858R) EGFR mutations 
[123]. After promising results in NSCLC patients, a Phase 
III clinical trial (LUX-Head&Neck) is being conducted in 
HNSCC patients to compare the efficacy and safety of 
afatinib as an adjuvant therapy for patients who have re-
ceived definitive, concurrent cisplatin-based chemoradio-
therapy. A recent phase II multicenter trial (NCT01538381), 
evaluated the intervention of the pre-operative activity of 
afatinib vs. nontreatment in HNSCC. Preliminary results 
demonstrated a tumor volume reduction assessed by FDG-
PET (18F-fluorodeoxyglucose-positron emission tomogra-
phy). The association of afatinib and other chemotherapeutic 
agents has been evaluated in a clinical trial I/II 
(NCT01721525) investigating a new chemotherapy regimen 
based on two oral drugs and two intravenous drugs (Afatinib, 
Ribavirin and Carboplatin/Paclitaxel). The efficacy and 
safety of afatinib was recently demonstrated in the LUX-
Head&Neck 1 trial. This is a Phase III, randomized, open-
label trial (NCT01345682) that evaluated afatinib efficacy 
and safety vs. methotrexate in 483 patients with recurrent or 
metastatic HNSCC after platinum-based therapy. Afatinib 
showed a significant increase in PFS (p = 0·030). Moreover 
it had a tolerable side effect profile [124]. 
 AST1306 (Allist Pharmaceuticals Inc.), N-[4-[3-chloro-
4-[(3- fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-
enamide (Fig. 2B), also known as Allitinib,® is a potent anti-
EGFR with irreversible action. In addition, it has an affinity 
for other EGFR family member proteins (HER2 and HER4) 
and exhibits significant antineoplastic activity in vitro and in 
vivo [125]. A recent clinical trial conducted in patients with 
solid tumors showed a preliminary anti-tumor effect and 
stable disease for6 months in 7 patients (ChiCTR-ONC-
10000893). Despite these promising results, AST1306 has 
not been tested in head and neck cancer patients.  
 PF-00299804 (Dacomitinib®, Pfizer Inc.) (E)-N-(4-(3-
chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-
(piperidin-1-yl)but-2-enamide (Fig. 2C) is an irreversible 
pan-Her inhibitor with cytotoxicity activity in tumor 
xenograft models that express HER family members, and 
efficient inhibition in double EGFR (L858R/T790M) muta-
tion [126]. Recently, a phase II trial showed positive results 
in metastatic HNSCC, in which 57% of patients (36/69) 
maintained stable disease and treatment had acceptable tox-
icity levels (NCT01737008) [127].  
 EKB-569 (Wyeth Inc.), (E)-N-(4-(3-chloro-4-fluorophen- 
ylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino) 
but-2-enamide (Fig. 2D), also known as Pelitinib,® is an 
irreversible EGFR inhibitor that has shown potential anti-
neoplastic effects in solid tumors [128]. Recently, a Phase I 
trial was conducted to determine the dosing for acceptable 
toxicity levels and induced therapy responses of EKB-559 
[129]. Pre-clinical studies, using squamous cell carcinoma 
suggest that EKB-569 increases sensitivity to radiotherapy 
[130]. At present, no clinical trial has been conducted in 
HNSCC patients.  
 CNX-2006, (Clovis Oncology, Inc.) N-[3-[[2-[4-[[1-(2-
fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-5-(trifl- 
uoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide 
(Fig. 2E) is an irreversible EGFR inhibitor that inhibits acti-
vating mutations of EGFR with high affinity as well as cells 
harboring the T790M mutation [131]. Although, in initial 
stages few studies have been conducted with CNX-2006 in 
HNSCC models, we believe that clinical trials will soon fol-
low due to its EGFR inhibitory potential.  
 AZD9291, (AstraZeneca. Inc.) N-[2-[2-(dimethylamino) 
ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)- 
pyrimidin-2-yl]amino]phenyl]prop-2-enamide is a potent 
irreversible mutant-selective EGFR inhibitor also known as 
Osimertinib (Fig. 2F). Initially clinical trials with this inhibi-
tor demonstrated a clinical benefit in lung cancer patients 
with a L858R/T790M EGFR mutation [132]. In November 
2015, AZD9291 (Tagrisso
TM
) was approved by the FDA for 
the treatment of patients with metastatic EGFR T790M mu-
tation-positive NSCLC that was resistant to first-generation 
EGFR TKI therapy [133]. However, our search for this re-
view did not any clinical and preclinical approaches in head 
and neck cancer. Due to its potent EGFR wild-type inhibi-
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tory action [134], AZD9291 may be a promising candidate in 
head neck cancer therapy.  
 CO-1686 (Clovis Oncology, Inc.) 2-propenamide, N-[3-
[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluo- 
romethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide, also 
known as Rociletinib,® (Fig. 2G) is an irreversible inhibitor 
of EGFRwt and mutant-selective EGFR. The TIGER, I, II 
and III trials are recruiting patients with EGFR-mutated, 
advanced NSCLC after failure of at least one previous 
EGFR-directed TKI. The most recent clinical studies con-
ducted in NSCLC patients treated with CO-1686 showed a 
positive tumor response and sustained disease control [135]. 
Although, CO-1686 has been demonstrating promising re-
sults in preclinical models, no clinical trial has been con-
ducted in HNSCC.  
 Finally, EGFR antisense (EGFR AS) has been used in 
experimental models to evaluate its ability to inhibit the pro-
liferation of HNSCC cell lines [136]. This approach consists 
of innoculating EGFR antisense that binds to specific 
mRNAs to interfere with the endogenous expression of 
EGFR. EGFR antisense results in a dysfunctional, mature 
protein, thereby reducing the activity of the ligand-binding 
domain and the kinase domain [136]. In nude mice 
xenografts, intratumoral plasmids that were injected with 
antisense EGFR sequences showed reduced tumor volumes 
when compared with the control group [137]. Subsequently, 
intralesional injections of EGFR liposomal antisense gene 
therapy in normal mice showed tolerable toxicity levels 
[138]. Based on the results, 17 patients with LAHNSCC 
were treated with intratumoral EGFR AS injections and afa-
vorable clinical response was observed in (5/17) of patients 
(29%) [139].  
5. PREDICTIVE BIOMARKERS TO ANTI-EGFR 
THERAPY IN HNSCC 
 Currently, the only anti-EGFR drug approved for 
HNSCC is cetuximab/panitumumab. A focus of great inter-
est has been on the identification of predictive biomarkers of 
clinical response to these drugs [140, 141]. Despite this ra-
tionale, a large body of evidence has showed that alteration 
of EGFR (protein overexpression, gene amplification) were 
not associated with patient response [141]. Intracellular 
pathways regulators, particularly, activating mutations of 
KRAS oncogene, were associated with mABs response [142]. 
The oncogene KRAS, drives signal transduction downstream 
of transmembrane receptor tyrosine kinases, especially the 
EGF receptor. However, KRAS mutations result in incessant 
activation of the intracellular RAS/MAPK/PI3K pathways, 
resulting in increased cell proliferation and survival, neoplas-
tic transformation, cell migration and metastasis [143]. Hot-
spot KRAS activating mutations are recognized as strong 
predictors of resistance to EGFR-mAbs (cetuximab or pani-
tumumab) in metastatic colorectal cancer (MCC) [142, 144, 
145]. In the last few decades, some in vitro findings have 
associated the low response rate to mAbs with an overex-
pression of the PI3K/AKT/mTOR pathway [146]. A seminal 
retrospective study of MCC showed that KRAS, BRAF, 
NRAS, and PIK3CA exon 20 mutations were significantly 
associated with a low cetuximab response rate [147].  
 In HNSCC, no predictive molecular marker of response 
to anti-EGFR agents is known. KRAS mutations are very rare 
(< 1%), while EGFR mutations represent less than 5% of 
HNSCCs [24]. Thus, the mutational status of EGFR and 
KRAS genes are not useful tools for predicting response to 
mAbs, due to low frequencies [148]. In HNSCC, other al-
terations may be associated with patient response, such as 
ligand levels, which have been associated to a few response 
rates for EGFR therapies. In vitro approaches in HNSCC cell 
lines, showed that the detection of values > or = 20pmol/L of 
amphiregulin are associated with increased efficiency of 
cetuximab and gefitinib, when compared to cell lines that 
have low amphiregulin expression [149]. These in vitro find-
ings were observed in 47 patients with HNSCC in which 
high expression of amphiregulin demonstrated significantly 
shortened OS (HR: 2.2, p = 0.002) and PFS (HR 2.2, p = 
0.019), compared with patients with low expression scores 
[150]. Other ligands such as HRG, have shown that signifi-
 
Fig. (2). Irreversible anti-EGFR molecules with therapeutic potential in head and neck cancer. A- Afatinib (Gilotrif
®
 - Boehringer Ingelheim 
Pharmaceuticals, Inc. B- Allitinib (Allist Pharmaceuticals, Inc.); C- PF-00299804 (Dacomitinib
®
 - Pfizer Inc); D- EKB-569 (Pelitinib
®
 - 
Wyeth Inc.); E- CNX-2006 (Clovis Oncology, Inc.); F-  AZD9291 (AstraZeneca); G- CO-1686 (Rociletinib
®
 - Clovis Oncology, Inc.) 
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cantly increased levels of expression in HNSCC patients is 
preferably associated with HER3 activation and defines a 
biologically distinct subset of patients, with a positive corre-
lation with cetuximab/cisplatin response [151]. 
 TGF- overexpression, was implicated in cetuximab re-
sistance in cell lines [152]. Interestingly, the whole expres-
sion profile of xenograft models using cetuximab-resistant 
colorectal cancer cell lines showed that phosphorylated MET 
was detected in resistant cell lines. The authors associate the 
increase in MET phosphorylation levels with TGF- overex-
pression [152]. Regarding HNSCC, TGF- overexpression is 
related to de novo and acquired resistance to EGFR-targeted 
mAbs, and supply a rationale for TGF- combination thera-
pies [153]. 
 Another hypothesis suggests that, EGFR nuclear translo-
cation is mediated by the Scr kinase family and overexpres-
sion of HER ligands (EGF, ARG, HB-EGF) leads to a 
cetuximab-resistant phenotype [79]. In HNSCC, EGFR nu-
clear translocation is associated with cetuximab/radiation 
therapeutic response. In this study, HNSCC cell lines treated 
with this combination showed elevated levels of nuclear 
EGFR and consequently a resistance phenotype, while 
Dasatinib therapy combination can inhibit EGFR transloca-
tion and restore cetuximab sensitivity [154]. 
5. CURRENT & FUTURE DEVELOPMENTS  
 EGFR inhibitors represent a class of chemotherapeutic 
agents with promising results in monotherapy or in combina-
tion with other anticancer agents. HNSCC tumors frequently 
exhibit very high expression of EGFR and anti-EGFR, and 
Cetuximab is the only targeted therapy approved for HNSCC 
treatment. However, a subgroup of HNSCC patients demon-
strate a response to cetuximab monotherapy, although the 
underlying mechanisms of this response remain ill-defined 
and there is no biomarker to predict responders. 
 The studies reported in this review reveal the potential of 
the newest generation of tyrosine kinase inhibitors, which are 
mainly being designed for the effective inhibition of the 
EGFR and other tyrosine kinase receptors simultaneouslys. 
Moreover, the development of multi-targeted therapies and 
irreversible anti-EGFR inhibitors reveals new perspectives in 
clinical trials and future treatment regimens. Third-
generation EGFR inhibitors, include afatinib, and is currently 
being tested in HNSCC patients. The multi-modality treat-
ment adopted in HNSCC frequently impacts quality of life 
due to extensive surgeries and toxicities related to intensive 
chemo-radiation approaches. Targeted therapies are becom-
ing increasingly adopted for the treatment of various tumor 
types due to their ability to adopt efficient and selective 
mechanisms of action, which limits cytotoxicity when com-
pared to conventional chemotherapeutic agents. Thus, the 
evaluation of new generation tyrosine kinase inhibitors in 
clinical trials, which includes HNSCC patients, and the 
search for molecular markers that predict sensitivity to these 
drugs, are of great importance to successfully improve the 
treatment of these patients. 
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